Literature DB >> 19760542

Improving care at cystic fibrosis centers through quality improvement.

Nathan C Kraynack1, John T McBride.   

Abstract

Quality improvement (QI) using a clinical microsystems approach provides cystic fibrosis (CF) centers the opportunity to make a significant positive impact on the health of their patients. The availability of center-specific outcomes data and the support of the Cystic Fibrosis Foundation are important advantages for these quality improvement efforts. This article illustrates how the clinical microsystems methodology can improve care delivery and outcomes by describing the gradual application of quality improvement principles over the past 5 years by the CF team at the Lewis Walker Cystic Fibrosis Center at Akron Children's Hospital in Akron, Ohio. Using the example of a project to improve the pulmonary function of the pediatric patients at our center as a framework, we describe the QI process from the initial team-building phase, through the assessment of care processes, standardization of care, and developing a culture of continuous improvement. We outline how enthusiastic commitment from physician leadership, clinical managers and central administration, the availability of coaches, and an appreciation of the importance of measurement, patient involvement, communication, and standardization are critical components for successful process improvement. Copyright Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2009        PMID: 19760542     DOI: 10.1055/s-0029-1238913

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  14 in total

1.  Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

Authors:  Alex H Gifford; Diana M Alexandru; Zhigang Li; Dana B Dorman; Lisa A Moulton; Katherine E Price; Thomas H Hampton; Mitchell L Sogin; Jonathan B Zuckerman; H Worth Parker; Bruce A Stanton; George A O'Toole
Journal:  J Cyst Fibros       Date:  2013-12-13       Impact factor: 5.482

2.  Implementation of cystic fibrosis clinical pathways improved physician adherence to care guidelines.

Authors:  Sachinkumar B Singh; Annie U Shelton; Barbara Greenberg; Timothy D Starner
Journal:  Pediatr Pulmonol       Date:  2016-10-31

3.  Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations.

Authors:  Jonathan D Cogen; Assaf P Oron; Ronald L Gibson; Lucas R Hoffman; Matthew P Kronman; Thida Ong; Margaret Rosenfeld
Journal:  Pediatrics       Date:  2017-02       Impact factor: 7.124

4.  Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.

Authors:  Elissa Charlotte Briggs; Thuan Nguyen; Michael Abraham Wall; Kelvin David MacDonald
Journal:  Clin Respir J       Date:  2011-08-09       Impact factor: 2.570

5.  Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Authors:  Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie
Journal:  Clin Transl Sci       Date:  2015-12-08       Impact factor: 4.689

6.  Genetic Variation Near chrXq22-q23 Is Linked to Emotional Functioning in Cystic Fibrosis.

Authors:  Eric Barbato; Barbara Daly; Sara Douglas; Mary Kerr; Paul Litman; Rebecca Darrah
Journal:  Biol Res Nurs       Date:  2020-05-11       Impact factor: 2.522

7.  Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study.

Authors:  Kristina L Bailey; Peter J Murphy; Olena K Lineberry; Matthew R Haack; John D Dickinson; Andre C Kalil
Journal:  J Investig Med       Date:  2020-01-21       Impact factor: 2.895

8.  One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.

Authors:  Corinne A Muirhead; Jillian N Sanford; Benjamin G McCullar; Dawn Nolt; Kelvin D MacDonald
Journal:  Clin Med Insights Pediatr       Date:  2016-07-12

Review 9.  Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.

Authors:  Kate Skolnik; Bradley S Quon
Journal:  F1000Res       Date:  2018-05-14

10.  Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.

Authors:  Katie Stokem; Jonathan B Zuckerman; David P Nicolau; Minkey Wungwattana; Edmund H Sears
Journal:  Respir Med Case Rep       Date:  2017-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.